Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3165
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
Artificial intelligence (AI) is reshaping neuroimaging workflows for Alzheimer's disease (AD) diagnosis, particularly through PET and MRI analysis advances. Since the FDA approval of Tauvid, a PET tracer targeting tau pathology, there has been a notable increase in studies applying AI to neuroimaging data. This narrative review synthesizes recent, high-impact literature to highlight clinically relevant AI applications in AD imaging. This review examined peer-reviewed studies published between January 2020 and January 2025, focusing on the use of AI, including machine learning, deep learning, and hybrid models for diagnostic and prognostic tasks in AD using PET and/or MRI. Studies were identified through targeted PubMed, Scopus, and Embase searches, emphasizing methodological diversity and clinical relevance. A total of 111 studies were categorized into five thematic areas: Image preprocessing and segmentation, diagnostic classification, prognosis and disease staging, multimodal data fusion, and emerging innovations. Deep learning models such as convolutional neural networks (CNNs), generative adversarial networks (GANs), and transformer-based architectures were widely employed by the research community in the field of AD. At the same time, several models reported strong diagnostic performance, but methodological challenges such as reproducibility, small sample sizes, and lack of external validation limit clinical translation. Trends in explainable AI, synthetic imaging, and integration of clinical biomarkers are also discussed. AI is rapidly advancing the field of AD imaging, offering tools for enhanced segmentation, staging, and early diagnosis. Multimodal approaches and biomarker-guided models show particular promise. However, future research must focus on reproducibility, interpretability, and standardized validation to bridge the gap between research and clinical practice.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387124 | PMC |
http://dx.doi.org/10.3390/jcm14165913 | DOI Listing |